Literature DB >> 11090543

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Z Yu1, F Xu, L M Huse, C Morisseau, A J Draper, J W Newman, C Parker, L Graham, M M Engler, B D Hammock, D C Zeldin, D L Kroetz.   

Abstract

The cytochrome P450-derived epoxyeicosatrienoic acids (EETs) have potent effects on renal vascular reactivity and tubular sodium and water transport; however, the role of these eicosanoids in the pathogenesis of hypertension is controversial. The current study examined the hydrolysis of the EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs) as a mechanism for regulation of EET activity and blood pressure. EET hydrolysis was increased 5- to 54-fold in renal cortical S9 fractions from the spontaneously hypertensive rat (SHR) relative to the normotensive Wistar-Kyoto (WKY) rat. This increase was most significant for the 14,15-EET regioisomer, and there was a clear preference for hydrolysis of 14, 15-EET over the 8,9- and 11,12-EETs. Increased EET hydrolysis was consistent with increased expression of soluble epoxide hydrolase (sEH) in the SHR renal microsomes and cytosol relative to the WKY samples. The urinary excretion of 14,15-DHET was 2.6-fold higher in the SHR than in the WKY rat, confirming increased EET hydrolysis in the SHR in vivo. Blood pressure was decreased 22+/-4 mm Hg (P:<0.01) 6 hours after treatment of SHRs with the selective sEH inhibitor N:, N:'-dicyclohexylurea; this treatment had no effect on blood pressure in the WKY rat. These studies identify sEH as a novel therapeutic target for control of blood pressure. The identification of a potent and selective inhibitor of EET hydrolysis will be invaluable in separating the vascular effects of the EET and DHET eicosanoids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090543     DOI: 10.1161/01.res.87.11.992

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  187 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

Review 2.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

3.  N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase.

Authors:  Hsin-Han Hou; Bruce D Hammock; Kou-Hui Su; Christophe Morisseau; Yu Ru Kou; Susumu Imaoka; Ami Oguro; Song-Kun Shyue; Jin-Feng Zhao; Tzong-Shyuan Lee
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

Review 4.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

Review 5.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

6.  Modulation by salt intake of the vascular response mediated through adenosine A(2A) receptor: role of CYP epoxygenase and soluble epoxide hydrolase.

Authors:  Mohammed A Nayeem; Darryl C Zeldin; Matthew A Boegehold; Christophe Morisseau; Anne Marowsky; Dovenia S Ponnoth; Kevin P Roush; John R Falck
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

7.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

8.  The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation.

Authors:  Pei H Cui; Nenad Petrovic; Michael Murray
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 9.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

Review 10.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.